-
公开(公告)号：US08435943B2
公开(公告)日：2013-05-07
申请号：US13089683
申请日：2011-04-19
CPC分类号： A61K38/1875 , A61K9/19 , A61K47/183 , A61K47/26 , A61K47/42
摘要： The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.
摘要翻译： 本发明涉及在各种冻干制剂和组合物中稳定骨形态发生蛋白。 本发明包括主要包括海藻糖作为冻干组合物的赋形剂及其随后的储存和重构的制剂，还可任选地包括其它赋形剂，包括缓冲液和表面活性剂。
-
公开(公告)号：US20110237506A1
公开(公告)日：2011-09-29
申请号：US13089683
申请日：2011-04-19
CPC分类号： A61K38/1875 , A61K9/19 , A61K47/183 , A61K47/26 , A61K47/42
摘要： The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.
摘要翻译： 本发明涉及在各种冻干制剂和组合物中稳定骨形态发生蛋白。 本发明包括主要包括海藻糖作为冻干组合物的赋形剂及其随后的储存和重构的制剂，还可任选地包括其它赋形剂，包括缓冲液和表面活性剂。
-
公开(公告)号：US20080147077A1
公开(公告)日：2008-06-19
申请号：US11950127
申请日：2007-12-04
CPC分类号： A61K38/1875 , A61K9/19 , A61K47/183 , A61K47/26 , A61K47/42
摘要： The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.
摘要翻译： 本发明涉及在各种冻干制剂和组合物中稳定骨形态发生蛋白。 本发明包括主要包括海藻糖作为冻干组合物的赋形剂及其随后的储存和重构的制剂，还可任选地包括其它赋形剂，包括缓冲液和表面活性剂。
-
公开(公告)号：US07956028B2
公开(公告)日：2011-06-07
申请号：US11950127
申请日：2007-12-04
IPC分类号： A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , C07K14/00 , C07K14/435 , C07K14/46 , C07K14/47 , C07K14/475 , C07K14/51
CPC分类号： A61K38/1875 , A61K9/19 , A61K47/183 , A61K47/26 , A61K47/42
摘要： The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants.
摘要翻译： 本发明涉及在各种冻干制剂和组合物中稳定骨形态发生蛋白。 本发明包括主要包括海藻糖作为冻干组合物的赋形剂及其随后的储存和重构的制剂，还可任选地包括其它赋形剂，包括缓冲液和表面活性剂。
-
公开(公告)号：US08524662B2
公开(公告)日：2013-09-03
申请号：US12979972
申请日：2010-12-28
申请人： Ben Byers , Dongling Su , Julia Hwang
发明人： Ben Byers , Dongling Su , Julia Hwang
CPC分类号： A61K31/728 , A61K38/1875 , A61K2300/00
摘要： Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.
摘要翻译： 公开了用于治疗骨关节炎的关节内注射的方法和组合物。 包括透明质酸和骨形态发生蛋白（如rhGDF-5）的组合的方法和组合物可用于任何滑膜关节，包括膝盖，肩部，髋，踝，踝关节，手，脊柱小面或颞下颌关节， 缓解疼痛和减缓疾病进展。
-
公开(公告)号：US07964561B2
公开(公告)日：2011-06-21
申请号：US12695357
申请日：2010-01-28
申请人： Venkata Garigapati , Dongling Su , Julius Lopez
发明人： Venkata Garigapati , Dongling Su , Julius Lopez
CPC分类号： A61K38/1875 , A61K47/18 , A61K47/183 , A61K47/26
摘要： Liquid formulations of bone morphogenetic proteins are provided for prolonged use at elevated temperatures. More specifically, the invention relates to liquid formulations comprising rhGDF-5, trehalose, and one or more biocompatible excipients that provide stability to the protein for at least 30 days at temperatures up to body temperature.
摘要翻译： 提供骨形态发生蛋白的液体制剂用于在升高的温度下长时间使用。 更具体地，本发明涉及包含rhGDF-5，海藻糖和一种或多种生物相容性赋形剂的液体制剂，其在至多体温的温度下提供蛋白质至少30天的稳定性。
-
公开(公告)号：US20050025834A1
公开(公告)日：2005-02-03
申请号：US10877761
申请日：2004-06-25
申请人： Hong Guo , Jianbing Chen , Dongling Su , Paul Ashton
发明人： Hong Guo , Jianbing Chen , Dongling Su , Paul Ashton
IPC分类号： A61K9/00 , A61K9/50 , A61K31/382 , A61K31/485 , A61K31/542 , A61K9/14
CPC分类号： A61K38/385 , A61K9/0019 , A61K9/0024 , A61K9/0051 , A61K9/0092 , A61K9/5031 , A61K31/382 , A61K31/485 , A61K31/542
摘要： The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.
摘要翻译： 本发明涉及缓释药物递送系统，包含所述系统的医疗装置及其使用和制造方法。 本发明的系统具有包括生物相容性固体和生物相容性流体组合物以实现期望的持续释放药物递送的生物可腐蚀药物递送装置。
-
公开(公告)号：US08815284B2
公开(公告)日：2014-08-26
申请号：US10877761
申请日：2004-06-25
申请人： Hong Guo , Jianbing Chen , Dongling Su , Paul Ashton
发明人： Hong Guo , Jianbing Chen , Dongling Su , Paul Ashton
IPC分类号： A61K9/66
CPC分类号： A61K38/385 , A61K9/0019 , A61K9/0024 , A61K9/0051 , A61K9/0092 , A61K9/5031 , A61K31/382 , A61K31/485 , A61K31/542
摘要： The present invention relates to sustained release drug delivery systems, medical devices incorporating said systems, and methods of use and manufacture thereof. The inventive systems feature bioerodible drug delivery devices that include biocompatible solid and biocompatible fluid compositions to achieve desired sustained release drug delivery.
摘要翻译： 本发明涉及缓释药物递送系统，包含所述系统的医疗装置及其使用和制造方法。 本发明的系统具有包括生物相容性固体和生物相容性流体组合物以实现期望的持续释放药物递送的生物可腐蚀药物递送装置。
-
公开(公告)号：US20130005681A1
公开(公告)日：2013-01-03
申请号：US13173658
申请日：2011-06-30
申请人： Dongling Su , Julia Hwang , Brooks J. Story
发明人： Dongling Su , Julia Hwang , Brooks J. Story
IPC分类号： A61K31/728 , A61P29/00 , A61P19/04 , A61P19/02
CPC分类号： A61K47/26 , A61K9/0019 , A61K9/19 , A61K31/726 , A61K31/728 , A61K31/737 , A61K47/02 , A61K47/10 , A61K2300/00
摘要： Compositions and methods are provided for treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid (“HA”), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans (“GAG”) or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate (“CS”), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine (“GlcN”).
摘要翻译： 提供组合物和方法用于治疗关节病，例如骨关节炎和/或与之相关的疼痛。 组合物和方法利用第一组分，即透明质酸（HA）与至少一种稳定剂的组合。 组合物可以包括增加HA的稳定性和保质期的稳定剂。 在另一个实施方案中，组合物和方法还可以包括另外的组分，例如一种或多种糖胺聚糖（GAG）或GAG前体。 GAG或GAG前体的实例可包括硫酸软骨素（CS），硫酸皮肤素，肝素，硫酸乙酰肝素，硫酸角质素和葡糖胺（GlcN）。
-
公开(公告)号：US07947649B2
公开(公告)日：2011-05-24
申请号：US12420260
申请日：2009-04-08
申请人： Dongling Su , Julius Lopez
发明人： Dongling Su , Julius Lopez
IPC分类号： A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , C07K14/00 , C07K14/435 , C07K14/46 , C07K14/47 , C07K14/475
CPC分类号： A61K9/0019 , A61K38/1875 , A61K47/12
摘要： Improved formulations and methods are provided for stabilizing a solution of bone morphogenetic protein. The compositions comprise an acetate buffered solution of GDF-5 and other excipients wherein the solution has a pH of from about 4.2 to about 5.3, thereby providing for a biologically isotonic solution having improved stability of the GDF-5 protein during storage, handling, and use.
摘要翻译： 提供改进的制剂和方法用于稳定骨形态发生蛋白的溶液。 所述组合物包含GDF-5和其它赋形剂的乙酸盐缓冲溶液，其中所述溶液的pH为约4.2至约5.3，从而提供具有改善的GDF-5蛋白在储存，处理和/或储存期间的稳定性的生物等渗溶液 使用。
-
-
-
-
-
-
-
-
-
搜索结果
24 条记录 (耗时 0.035 秒)
